# reload+after+2024-01-21 03:45:59.429908
address1§1775 West Oak Commons Court, NE
city§Marietta
state§GA
zip§30062
country§United States
phone§770 651 9100
website§https://www.mimedx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.
fullTimeEmployees§867
companyOfficers§[{'maxAge': 1, 'name': 'Mr. William F. Hulse IV', 'age': 49, 'title': 'General Counsel & Chief Administrative Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 677364, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert Benjamin Stein M.D., Ph.D.', 'age': 72, 'title': 'President of Regenerative Medicine & Biologics Innovation', 'yearBorn': 1951, 'fiscalYear': 2022, 'totalPay': 639284, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joseph H. Capper', 'age': 59, 'title': 'CEO & Director', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Douglas C. Rice CPA', 'age': 57, 'title': 'Chief Financial Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Scott M. Turner', 'age': 57, 'title': 'Senior Vice President of Operations & Procurement', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 493975, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Matthew M. Notarianni', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark P. Graves', 'age': 57, 'title': 'Senior VP & Chief Compliance Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Hilary  Dixon', 'title': 'Vice President of Investor Relations & Corporate Strategic Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kate  Surdez', 'title': 'Chief Human Resources Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David H. Mason Jr.', 'age': 76, 'title': 'Chief Medical Officer', 'yearBorn': 1947, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§2
compensationRisk§3
shareHolderRightsRisk§5
overallRisk§3
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.488
priceToSalesTrailing12Months§3.694714
currency§USD
dateShortInterest§1702598400
forwardEps§0.31
pegRatio§5.17
exchange§NCM
quoteType§EQUITY
shortName§MiMedx Group, Inc
longName§MiMedx Group, Inc.
firstTradeDateEpochUtc§1202826600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f94c0942-c42c-3ae5-83ee-5792f556733a
gmtOffSetMilliseconds§-18000000
targetHighPrice§12.0
targetLowPrice§11.0
targetMeanPrice§11.65
targetMedianPrice§12.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§2.984
grossMargins§0.8215
ebitdaMargins§0.06621
trailingPegRatio§None
